Forte Biosciences Inc. (FBRX)
NASDAQ: FBRX
· Real-Time Price · USD
15.00
-0.86 (-5.42%)
At close: Sep 24, 2025, 3:59 PM
15.00
0.00%
After-hours: Sep 24, 2025, 06:46 PM EDT
-5.42% (1D)
| Bid | 14.67 |
| Market Cap | 186.49M |
| Revenue (ttm) | 38K |
| Net Income (ttm) | -42.45M |
| EPS (ttm) | -3.68 |
| PE Ratio (ttm) | -4.08 |
| Forward PE | -4.44 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 15.39 |
| Volume | 82,020 |
| Avg. Volume (20D) | 103,323 |
| Open | 16.15 |
| Previous Close | 15.86 |
| Day's Range | 14.90 - 16.15 |
| 52-Week Range | 4.11 - 28.68 |
| Beta | 2.69 |
| Ex-Dividend Date | n/a |
About FBRX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol FBRX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for FBRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
+2.94%
Forte Biosciences shares are trading higher after ...
Unlock content with
Pro Subscription
3 months ago
-25.26%
Forte Biosciences shares are trading lower after the company announced the pricing of a $75 million public offering.
3 months ago · businesswire.com
Forte Biosciences Announces Pricing of $75 Million Public OfferingDALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a publ...
